CRISPR Therapeutics
CRSP
521 hedge funds and large institutions have $4.16B invested in CRISPR Therapeutics in 2026 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 156 increasing their positions, 139 reducing their positions, and 47 closing their positions.
77% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 47
13% more capital invested
Capital invested by funds: $3.67B → $4.16B (+$488M)
12% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 139
6% more funds holding
Funds holding: 491 → 521 (+30)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less call options, than puts
Call options by funds: $92.8M | Put options by funds: $95.6M
1.33% less ownership
Funds ownership: 80.36% → 79.03% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$47.1M |
| 2 |
BlackRock
New York
|
+$35.3M |
| 3 |
Two Sigma Investments
New York
|
+$26.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$17.9M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$97.7M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$47.4M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$46.1M |
| 4 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$34.6M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$23.5M |
CRSP Hedge Fund Activity: Q2 2026 in Review
521 of the 8,286 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2026, worth a combined $4.16B — up 13% from $3.67B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new CRSP positions and 47 closed out — a net gain of 36 holders — while 156 added to existing stakes and 139 trimmed.
The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $47.1M. The largest seller was ARK Investment Management, cutting an estimated $97.7M.
- 521 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2026, up from 491 in Q1 2026.
- Funds reported $4.16B of CRISPR Therapeutics stock for Q2 2026, up 13% quarter-over-quarter.
- 83 funds opened new CRISPR Therapeutics positions in Q2 2026 and 47 closed out, a net change of +36 holders.
- The largest CRISPR Therapeutics buyer in Q2 2026 was D.E. Shaw & Co, an estimated $47.1M added.
- The largest CRISPR Therapeutics seller in Q2 2026 was ARK Investment Management, an estimated $97.7M sold.
Based on aggregated 13F filings for Q2 2026.